Groundbreaking Study Validates Esopredict® as Essential Tool for Barrett's Esophagus Prognosis
The recently published research in the American Journal of Gastroenterology highlights a pivotal advancement for the Esopredict® test, a diagnostic tool developed by the gastrointestinal health company Previse. This study brings forth compelling evidence that Esopredict® is instrumental in assessing the risk of neoplastic progression in patients with precancerous Barrett's esophagus, solidifying its status as the only commercially available test leveraging DNA methylation for this purpose.
The research titled "Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Barrett's Esophagus Patients" elucidates the robust performance of Esopredict® across various locations and times within each patient. During the study, biopsies were taken from different sites within the Barrett's segment during endoscopic examinations, reflecting both spatial and temporal analysis. Remarkably, regardless of the biopsy location or the time of the procedure, Esopredict® demonstrated consistent performance. This finding assures gastroenterologists of the reliability of Esopredict®, offering actionable insights that can greatly aid in clinical decision-making.
Dr. Sarah Laun, Vice President of Research and Development at Previse, emphasized the pressing need for precise identification of Barrett's patients at risk for esophageal cancer. "Gastroenterologists have expressed the necessity for enhanced risk stratification in Barrett's esophagus patients, and this study’s results firmly support the ability of Esopredict® to provide these critical insights," she stated, underlining the test's role in optimizing patient management and improving health outcomes.
Barrett's esophagus is acknowledged as the sole precursor to esophageal adenocarcinoma (EAC), a highly lethal form of cancer that is experiencing a rising incidence. Previse is dedicated to pioneering research aimed at enhancing patient outcomes, and the validation of Esopredict® marks a significant step forward in the management of Barrett's esophagus. Daniel Lunz, the CEO of Previse, highlighted the study’s importance, stating, "This is a critical advancement for Esopredict, affirming its effectiveness as a risk stratification solution that can facilitate earlier interventions for high-risk patients while minimizing unnecessary procedures for those considered low-risk."
For patients diagnosed with Barrett's esophagus, the implications of these findings are profound. With Esopredict®, healthcare providers can make more informed and timely treatment decisions, reducing the potential for aggressive interventions by accurately identifying lower-risk patients. Moreover, the test's two-week turnaround time post-sample receipt allows gastroenterologists to promptly plan follow-up care, marking a significant win in the fight against esophageal cancer.
Previse, founded in 2018, focuses on chronic acid reflux-related diseases and is committed to preventing and early detection of gastrointestinal conditions. At the heart of their mission is the cutting-edge biomarker technology developed by Dr. Stephen Meltzer and his research team at Johns Hopkins University. This technology, backed by extensive NIH funding and years of dedicated research, forms the backbone of Previse’s work combating GI diseases, including cancer.
In conclusion, the publication reaffirms Esopredict®'s pivotal role in the realm of Barrett's esophagus care, equipping clinicians with the necessary tools to navigate this complex disease landscape effectively. For more insights into Esopredict® and further details on the study, interested parties can visit www.previsedx.com or reach out directly to the Previse team.
The research titled "Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Barrett's Esophagus Patients" elucidates the robust performance of Esopredict® across various locations and times within each patient. During the study, biopsies were taken from different sites within the Barrett's segment during endoscopic examinations, reflecting both spatial and temporal analysis. Remarkably, regardless of the biopsy location or the time of the procedure, Esopredict® demonstrated consistent performance. This finding assures gastroenterologists of the reliability of Esopredict®, offering actionable insights that can greatly aid in clinical decision-making.
Dr. Sarah Laun, Vice President of Research and Development at Previse, emphasized the pressing need for precise identification of Barrett's patients at risk for esophageal cancer. "Gastroenterologists have expressed the necessity for enhanced risk stratification in Barrett's esophagus patients, and this study’s results firmly support the ability of Esopredict® to provide these critical insights," she stated, underlining the test's role in optimizing patient management and improving health outcomes.
Barrett's esophagus is acknowledged as the sole precursor to esophageal adenocarcinoma (EAC), a highly lethal form of cancer that is experiencing a rising incidence. Previse is dedicated to pioneering research aimed at enhancing patient outcomes, and the validation of Esopredict® marks a significant step forward in the management of Barrett's esophagus. Daniel Lunz, the CEO of Previse, highlighted the study’s importance, stating, "This is a critical advancement for Esopredict, affirming its effectiveness as a risk stratification solution that can facilitate earlier interventions for high-risk patients while minimizing unnecessary procedures for those considered low-risk."
For patients diagnosed with Barrett's esophagus, the implications of these findings are profound. With Esopredict®, healthcare providers can make more informed and timely treatment decisions, reducing the potential for aggressive interventions by accurately identifying lower-risk patients. Moreover, the test's two-week turnaround time post-sample receipt allows gastroenterologists to promptly plan follow-up care, marking a significant win in the fight against esophageal cancer.
Previse, founded in 2018, focuses on chronic acid reflux-related diseases and is committed to preventing and early detection of gastrointestinal conditions. At the heart of their mission is the cutting-edge biomarker technology developed by Dr. Stephen Meltzer and his research team at Johns Hopkins University. This technology, backed by extensive NIH funding and years of dedicated research, forms the backbone of Previse’s work combating GI diseases, including cancer.
In conclusion, the publication reaffirms Esopredict®'s pivotal role in the realm of Barrett's esophagus care, equipping clinicians with the necessary tools to navigate this complex disease landscape effectively. For more insights into Esopredict® and further details on the study, interested parties can visit www.previsedx.com or reach out directly to the Previse team.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.